EBS

SEC source: 0001190344-26-000010 · wk-form4_1772764688.xml · nonDerivative · entry 1

FOWLER JOHN D JR · CIK 0001190344 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,006

F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the day prior to the anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

SEC source: 0001196632-26-000009 · wk-form4_1772762821.xml · derivative · entry 2

LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 557,346

Underlying: Common Stock · 72,856 shares

Expires 2033-03-02

F2 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

SEC source: 0001989644-26-000005 · wk-form4_1772763598.xml · derivative · entry 2

Hartzel William · CIK 0001989644 · SVP, Bioservices

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 259,545

Underlying: Common Stock · 44,834 shares

Expires 2033-03-02

F2 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

SEC source: 0001961994-26-000009 · wk-form4_1772762934.xml · derivative · entry 2

Williams Paul Anthony · CIK 0001961994 · SVP, Products Business

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 254,948

Underlying: Common Stock · 44,834 shares

Expires 2033-03-02

F2 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

SEC source: 0001919170-26-000009 · wk-form4_1772762761.xml · derivative · entry 2

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 294,447

Underlying: Common Stock · 44,834 shares

Expires 2033-03-02

F2 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

SEC source: 0001196632-26-000006 · wk-form4_1772573548.xml · nonDerivative · entry 1

LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 239,017

F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units.

SEC source: 0001961994-26-000006 · wk-form4_1772573590.xml · nonDerivative · entry 1

Williams Paul Anthony · CIK 0001961994 · SVP, Products Business

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,078

F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units.

SEC source: 0001919170-26-000006 · wk-form4_1772572600.xml · nonDerivative · entry 1

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 112,307

F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units.

SEC source: 0001196632-26-000011 · wk-form4_1772805051.xml · derivative · entry 2

LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,321 shares

Expires 2026-02-25

F1 · kind: The reported stock options expired unexercised pursuant to their terms and no value was received.

F3 · derivative.exercise_date: Vested in three equal installments beginning on the day prior to the first anniversary of the date of grant, subject to continued service with the company.

SEC source: 0002043716-26-000002 · wk-form4_1770768677.xml · nonDerivative · entry 1

Perl Jessica · CIK 0002043716 · SVP, General Counsel, Corp Sec

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,469

F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units

SEC source: 0001196632-26-000003 · wk-form4_1770768376.xml · nonDerivative · entry 2

LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 239,700

F2 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units

SEC source: 0001196632-26-000003 · wk-form4_1770768376.xml · nonDerivative · entry 1

LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 245,342

F1 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to both cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025. On February 06, 2026, the final certification date, the Compensation Committee certified the achievement of the 2023-2025 PSUs at a payout factor of 25% of target resulting in the actual award of 15,384 shares of common stock, which is less than the 61,539 shares previously reported on March 02, 2023 and June 09, 2023.

SEC source: 0001919170-26-000003 · wk-form4_1770768563.xml · nonDerivative · entry 2

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 112,620

F2 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units

SEC source: 0001919170-26-000003 · wk-form4_1770768563.xml · nonDerivative · entry 1

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 115,472

F1 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to both cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025. On February 06, 2026, the final certification date, the Compensation Committee certified the achievement of the 2023-2025 PSUs at a payout factor of 25% of target resulting in the actual award of 9,615 shares of common stock, which is less than the 38,462 shares previously reported on March 02, 2023 and June 09, 2023.

SEC source: 0001961994-26-000003 · wk-form4_1770768441.xml · nonDerivative · entry 2

Williams Paul Anthony · CIK 0001961994 · SVP, Products Business

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,194

F2 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units

SEC source: 0001961994-26-000003 · wk-form4_1770768441.xml · nonDerivative · entry 1

Williams Paul Anthony · CIK 0001961994 · SVP, Products Business

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,216

F1 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to both cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025. On February 06, 2026, the final certification date, the Compensation Committee certified the achievement of the 2023-2025 PSUs at a payout factor of 25% of target resulting in the actual award of 2,884 shares of common stock, which is less than the 11,539 shares previously reported on March 02, 2023 and June 09, 2023.

SEC source: 0001989644-26-000002 · wk-form4_1770768411.xml · nonDerivative · entry 2

Hartzel William · CIK 0001989644 · SVP, Bioservices

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,681

F2 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units

SEC source: 0001989644-26-000002 · wk-form4_1770768411.xml · nonDerivative · entry 1

Hartzel William · CIK 0001989644 · SVP, Bioservices

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 97,311

F1 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to both cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025. On February 06, 2026, the final certification date, the Compensation Committee certified the achievement of the 2023-2025 PSUs at a payout factor of 25% of target resulting in the actual award of 1,922 shares of common stock, which is less than the 7,693 shares previously reported on March 02, 2023 and June 09, 2023.

SEC source: 0002044279-25-000003 · wk-form4_1765919534.xml · nonDerivative · entry 1

Lowry Simon C · CIK 0002044279 · SVP, R&D, CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 88,439

F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units.

SEC source: 0001380177-25-000006 · wk-form4_1765321258.xml · derivative · entry 5

Richard Ronald · CIK 0001380177 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,748 shares

Expires 2031-05-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, as compensation for Board and Committee service. The shares underlying the options exercised were fully vested on May 22, 2025.

SEC source: 0001380177-25-000006 · wk-form4_1765321258.xml · nonDerivative · entry 4

Richard Ronald · CIK 0001380177 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 98,417

F4 · price: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $11.88 to $11.97.

SEC source: 0001380177-25-000006 · wk-form4_1765321258.xml · nonDerivative · entry 3

Richard Ronald · CIK 0001380177 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 113,301

F3 · shares: Represents shares of common stock sold solely to satisfy the option exercise price and applicable taxes associated with the option exercise.

F4 · price: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $11.88 to $11.97.

SEC source: 0001380177-25-000006 · wk-form4_1765321258.xml · nonDerivative · entry 2

Richard Ronald · CIK 0001380177 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 124,165

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001380177-25-000006 · wk-form4_1765321258.xml · nonDerivative · entry 1

Richard Ronald · CIK 0001380177 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 98,417

F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated.

F2 · price: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $12.11 to $12.12.

SEC source: 0001989644-25-000006 · wk-form4_1763067684.xml · nonDerivative · entry 1

Hartzel William · CIK 0001989644 · SVP, Bioservices

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 103,082

F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units.

SEC source: 0001583098-25-000005 · wk-form4_1762981979.xml · nonDerivative · entry 1

DeGolyer Donald W · CIK 0001583098 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 119,858

F1 · shares: Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated August 11, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on October 2, 2025.

F2 · price: For reporting purposes, sales prices within a $1 range have been aggregated and the weighted average sales price has been reported. The price ranges were: $10.33 - $10.79. The Company maintains a record of the transactions and copies will be provided upon request.

SEC source: 0001536908-25-000006 · wk-form4_1762808960.xml · nonDerivative · entry 1

Dayal Sujata Tyagi · CIK 0001536908 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 88,980

F1 · shares: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on August 8, 2025 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2 · price: All shares sold at an exact price of $10.00.

SEC source: 0001196632-25-000004 · wk-form4_1760731355.xml · nonDerivative · entry 1

LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 291,497

F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units.

SEC source: 0001919170-25-000004 · wk-form4_1760646078.xml · nonDerivative · entry 1

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 144,319

F1 · shares: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on December 2, 2024 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2 · price: All shares sold at an exact price of $10.00.

SEC source: 0001628280-25-040670 · wk-form4_1755549206.xml · nonDerivative · entry 1

Zoon Kathryn C · CIK 0001685720 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 71,799

F1 · shares: Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated May 16, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on May 22, 2025 and May 25, 2025, respectively.

F2 · price: All shares sold at an exact price of $8.87.

SEC source: 0001628280-25-040156 · wk-form4_1755116574.xml · nonDerivative · entry 1

DeGolyer Donald W · CIK 0001583098 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 137,659

F1 · shares: Represents the number of shares sold by the Reporting Person to satisfy the Reporting Person's tax obligations resulting from the settlement of vested RSUs on May 22, 2025.

F2 · price: All shares sold at an exact price of $8.6475.

SEC source: 0001367644-25-000166 · wk-form4_1752609846.xml · nonDerivative · entry 1

Hartzel William · CIK 0001989644 · SVP, Bioservices

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 103,692

F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units.

SEC source: 0001367644-25-000138 · wk-form4_1749586014.xml · nonDerivative · entry 1

LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 296,492

F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units.

SEC source: 0001367644-25-000144 · wk-form4_1749586359.xml · nonDerivative · entry 1

Hartzel William · CIK 0001989644 · SVP, Bioservices

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,955

F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units.

SEC source: 0001367644-25-000143 · wk-form4_1749586350.xml · nonDerivative · entry 1

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 174,927

F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units.

SEC source: 0001367644-25-000142 · wk-form4_1749586339.xml · nonDerivative · entry 1

Williams Paul Anthony · CIK 0001961994 · SVP, Products Business

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,871

F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units.

SEC source: 0001367644-25-000136 · wk-form4_1748462897.xml · nonDerivative · entry 1

Katkin Keith · CIK 0001314596 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 86,431

F1 · shares: Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated November 8, 2024, for the purpose of satisfying tax obligations relating to the vesting of RSUs on May 22, 2025.

F2 · price: For reporting purposes, sales prices within a $1 range have been aggregated and the weighted average sales price has been reported. The price ranges were: $6.22 - $6.35. The Company maintains a record of the transactions and copies will be provided upon request.

SEC source: 0001367644-25-000127 · wk-form4_1747339349.xml · nonDerivative · entry 1

PAPA JOSEPH C · CIK 0001242215 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 342,500

F1 · price: On May 13, 2025, Mr. Papa purchased an aggregate of 60,000 shares of Emergent BioSolutions Inc. common stock. For reporting purposes, purchase prices within a $1 range have been aggregated and the weighted average purchase price has been reported. The price ranges were: $5.76 - $5.88. The Company maintains a record of the transactions and copies will be provided upon request.

SEC source: 0001196632-26-000011 · wk-form4_1772805051.xml · derivative · entry 1

LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 19,963 shares

Expires 2025-05-07

F1 · kind: The reported stock options expired unexercised pursuant to their terms and no value was received.

F2 · derivative.exercise_date: Vested in three equal installments on May 7, 2019, May 7, 2020 and May 7, 2021.

SEC source: 0001367644-25-000108 · wk-form4_1746232265.xml · derivative · entry 2

Zoon Kathryn C · CIK 0001685720 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,572

Underlying: Common Stock · 15,824 shares

Expires 2032-04-29

F2 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.

F3 · derivative.underlying_shares: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.

SEC source: 0001367644-25-000108 · wk-form4_1746232265.xml · nonDerivative · entry 1

Zoon Kathryn C · CIK 0001685720 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,885

F1 · shares: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.

SEC source: 0001367644-25-000109 · wk-form4_1746232276.xml · derivative · entry 2

Fowler Neal Franklin · CIK 0001493692 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,572

Underlying: Common Stock · 15,824 shares

Expires 2032-04-29

F2 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.

F3 · derivative.underlying_shares: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.

SEC source: 0001367644-25-000109 · wk-form4_1746232276.xml · nonDerivative · entry 1

Fowler Neal Franklin · CIK 0001493692 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,503

F1 · shares: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.

SEC source: 0001367644-25-000110 · wk-form4_1746232287.xml · derivative · entry 2

White Marvin L · CIK 0001493324 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,572

Underlying: Common Stock · 15,824 shares

Expires 2032-04-29

F2 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.

F3 · derivative.underlying_shares: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.

SEC source: 0001367644-25-000110 · wk-form4_1746232287.xml · nonDerivative · entry 1

White Marvin L · CIK 0001493324 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 88,495

F1 · shares: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.

SEC source: 0001367644-25-000103 · wk-form4_1746232211.xml · derivative · entry 2

SULLIVAN LOUIS W · CIK 0001193522 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,572

Underlying: Common Stock · 15,824 shares

Expires 2032-04-29

F2 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.

F3 · derivative.underlying_shares: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.

SEC source: 0001367644-25-000103 · wk-form4_1746232211.xml · nonDerivative · entry 1

SULLIVAN LOUIS W · CIK 0001193522 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 139,098

F1 · shares: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.

SEC source: 0001367644-25-000106 · wk-form4_1746232243.xml · derivative · entry 2

Katkin Keith · CIK 0001314596 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,572

Underlying: Common Stock · 15,824 shares

Expires 2032-04-29

F2 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.

F3 · derivative.underlying_shares: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.

SEC source: 0001367644-25-000106 · wk-form4_1746232243.xml · nonDerivative · entry 1

Katkin Keith · CIK 0001314596 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,275

F1 · shares: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.

SEC source: 0001367644-25-000111 · wk-form4_1746232297.xml · derivative · entry 2

Richard Ronald · CIK 0001380177 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,572

Underlying: Common Stock · 15,824 shares

Expires 2032-04-29

F2 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.

F3 · derivative.underlying_shares: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.